To investigate the potential therapeutic possibility of TEAD1 inhibition in cardiac remodeling, we evaluated the effects of the TEAD1 inhibitor VT103 on TAC-induced cardiac remodeling. The gene discussed is TEAD1; the disease is persistent truncus arteriosus.